Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)

被引：3

作者：

Lucchini, Elisa ^{[1
]}

Palandri, Francesca ^{[2
]}

Volpetti, Stefano ^{[1
]}

Vianelli, Nicola ^{[2
]}

Auteri, Giuseppe ^{[2
]}

Rossi, Elena ^{[3
]}

Patriarca, Andrea ^{[4
]}

Carli, Giuseppe ^{[5
]}

Barcellini, Wilma ^{[6
]}

Tosi, Patrizia ^{[7
]}

Consoli, Ugo ^{[8
]}

Valeri, Federica ^{[9
]}

Santoro, Cristina ^{[10
]}

Paoloni, Francesca ^{[11
]}

Fazi, Paola ^{[11
]}

Boggio, Elena ^{[12
]}

Dianzani, Umberto ^{[12
]}

Giardini, Ilaria ^{[13
]}

Carpenedo, Monica ^{[14
]}

Fanin, Renato ^{[15
]}

Zaja, Francesco ^{[16
]}

机构：

[1] Univ Udine, DAME, Ctr Trapianti & Terapie Cellulari C Melzi, Clin Ematol, Udine, Italy

[2] S Orsola Malpighi Bologna Univ Hosp, Inst Hematol L&A Seragnoli, Bologna, Italy

[3] Catholic Univ, Fdn Policlin Univ A Gemelli IRCCS, Sch Med, Inst Hematol, Rome, Italy

[4] AOU Maggiore Carita, UO Ematol, Novara, Italy

[5] Osped San Bortolo, Hematol Dept, Vicenza, Italy

[6] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, UOC Ematol, Milan, Italy

[7] Infermi Hosp Rimini, Hematol Unit, Rimini, Italy

[8] UOC Ematol ARNAS Garibaldi, Catania, Italy

[9] Ematol Univ, CRR Malattie Emorrag & Trombot Adulto, Citta Salute & Sci, Turin, Italy

[10] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Rome, Italy

[11] GIMEMA Fdn, Rome, Italy

[12] Univ Piemonte Orientale, Dept Hlth Sci, Lab Immunol, Novara, Italy

[13] Fdn IRCCS Policlin S Matteo, Lab Farmacocinet Clin & Sperimentale, Pavia, Italy

[14] ASST Osped San Gerardo, Hematol & Transplant Dept, Monza, Italy

[15] Azienda Sanitaria Univ Integrata Udine, Div Hematol & Bone Marrow Transplantat, Udine, Italy

[16] Azienda Sanitaria Univ Integrata, SC Ematol, Trieste, Italy

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-113314

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1135

引用

页数：4

共 10 条

[1] ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO ACHIEVE LONG-TERM REMISSION. UPDATED RESULTS OF A PHASE II, MULTICENTER, PROSPECTIVE STUDY BY GIMEMA GROUP (THE ESTIT STUDY)
Lucchini, E.
Palandri, F.
Volpetti, S.
Vianelli, N.
Auteri, G.
Rossi, E.
Patriarca, A.
Carli, G.
Barcellini, W.
Rotondo, F.
Consoli, U.
Valeri, F.
Santoro, C.
Crea, E.
Vignetti, M.
Boggio, E.
Dianzani, U.
Giardini, I.
Carpenedo, M.
Rodeghiero, F.
Fanin, R.
Zaja, F.
HAEMATOLOGICA, 2019, 104 : 32 - 32
[2] Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study
Lucchini, Elisa
Palandri, Francesca
Volpetti, Stefano
Vianelli, Nicola
Auteri, Giuseppe
Rossi, Elena
Patriarca, Andrea
Carli, Giuseppe
Barcellini, Wilma
Celli, Melania
Consoli, Ugo
Valeri, Federica
Santoro, Cristina
Crea, Enrico
Vignetti, Marco
Paoloni, Francesca
Gigliotti, Casimiro Luca
Boggio, Elena
Dianzani, Umberto
Giardini, Ilaria
Carpenedo, Monica
Rodeghiero, Francesco
Fanin, Renato
Zaja, Francesco
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (02) : 386 - 396
[3] Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study
Tjonnfjord, Eirik
Holme, Pal Andre
Darne, Bernadette
Khelif, Abderrahim
Waage, Anders
Michel, Marc
Ben Romdhan, Neila
Ghanima, Waleed
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (03) : 460 - 465
[4] Long-term survival of favorable-risk patients with metastatic renal cell carcinoma treated with second-line axitinib in a multicenter phase II study.
Tsimafeyeu, Ilya
Borisov, Pavel S.
Semenov, Andrey
Leonenkov, Roman
Novikova, Olga
Gamayunov, Sergey
Mikhailova, Nadezhda
Bondarenko, Anastasia
Abdelgafur, Ahmed
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[5] Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 PlaceboControlled, Double-Blind, Parallel-Group Study
Kuwana, Masataka
Ito, Tomoki
Kowata, Shugo
Hatta, Yoshihiro
Fujimaki, Katsumichi
Naito, Kensuke
Kurahashi, Shingo
Kagoo, Toshiya
Tanimoto, Kazuki
Shichiri, Natsuko
Saotome, So
Masuda, Esteban
Tomiyama, Yoshiaki
BLOOD, 2023, 142
[6] Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients
Decaux, Olivier
Renault, Alain
Sebille, Veronique
Moreau, Philippe
Attal, Michel
Voillat, Laurent
Pegourie, Brigitte
Tiab, Mourad
Facon, Thierry
Zerbib, Robert
Grosbois, Bernard
Bellissant, Eric
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (06): : 418 - 422
[7] Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a Phase II multicenter study (trans-Tasman radiation oncology group)
O'Brien, PC
Roos, DE
Pratt, G
Liew, KH
Barton, MB
Poulsen, MG
Olver, IN
Trotter, GE
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (02): : 408 - 413
[8] Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study
Kuwana, Masataka
Ito, Tomoki
Kowata, Shugo
Hatta, Yoshihiro
Fujimaki, Katsumichi
Naito, Kensuke
Kurahashi, Shingo
Kagoo, Toshiya
Tanimoto, Kazuki
Saotome, So
Tomiyama, Yoshiaki
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (02) : E55 - E59
[9] Long-Term Complications after Splenectomy in Adult Chronic Immune Thrombocytopenia with a Minimum Follow up of 10 Years. First Results from a Single-Center Case-Control Study in 140 Patients with Primary ITP
Thai, Lan-huong
Mahevas, Matthieu
Roudot-Thoraval, Francoise
Languille, Laetitia
Dumas, Guillaume
Khellaf, Mehdi
Bierling, Philippe
Michel, Marc
Godeau, Bertrand
BLOOD, 2014, 124 (21)
[10] Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer
Heigener, David F.
von Pawel, Joachim
Eschbach, Corinna
Brune, Andreas
Schmittel, Alexander
Schmelter, Thomas
Reck, Martin
Fischer, Juergen R.
LUNG CANCER, 2013, 80 (03) : 319 - 325

← 1 →